Market Overview

According to fortune business insights, the global neurovascular devices market is witnessing significant growth, driven by the increasing prevalence of neurological disorders, rising awareness of minimally invasive treatment options, and continuous technological advancements in interventional neurology. Neurovascular devices are specialized medical instruments used to diagnose and treat conditions affecting blood vessels in the brain, including cerebral aneurysms, ischemic strokes, and other cerebrovascular disorders.

According to Fortune Business Insights™, the global neurovascular devices market size was valued at USD 4.08 billion in 2025. The market is projected to grow from USD 4.46 billion in 2026 to USD 9.82 billion by 2034, exhibiting a CAGR of 10.40% during the forecast period (2026–2034). North America dominated the market, accounting for a 43.60% share in 2025.

The rising incidence of strokes and brain aneurysms, particularly among the aging population, is increasing the demand for effective neurovascular interventions. Furthermore, growing investments in research and development and the introduction of advanced embolization and thrombectomy technologies are supporting market expansion.

Major Players Profiled

  • Medtronic (U.S.)
  • Penumbra, Inc. (U.S.)
  • Stryker (U.S.)
  • Johnson & Johnson Services, Inc. (CERENOVUS) (U.S.)
  • MicroPort Scientific Corporation (China)
  • Acandis GmbH (Germany)
  • MicroVention, Inc. (U.S.)
  • NeuroVasc Technologies, Inc. (U.S.)
  • ASAHI INTECC CO., LTD. (Japan)
  • Perflow Medical Ltd. (Israel)

Market Segmentation

By Device Type: The market is segmented into stenting systems, embolization devices, neurothrombectomy devices, and support devices. The embolization devices segment dominated the market, accounting for 45.29% of the market share in 2026. Its leadership is supported by the growing number of cerebral aneurysm treatments and the introduction of advanced embolization technologies. Neurothrombectomy devices are also expected to experience considerable growth due to the increasing incidence of ischemic strokes and rising adoption of mechanical thrombectomy procedures.

By Application: The market is categorized into cerebral aneurysms, ischemic stroke, and others. The cerebral aneurysms segment represents a significant market share due to the increasing prevalence of aneurysms and the availability of advanced treatment technologies. Meanwhile, the ischemic stroke segment is anticipated to grow substantially as mechanical thrombectomy becomes increasingly important in managing acute ischemic stroke.

By End-user: The market is divided into hospitals, specialty clinics, and others. Hospitals are expected to dominate, accounting for 72.20% of the market share in 2026, supported by advanced medical infrastructure, higher patient admissions, and the availability of specialized neurointerventional facilities.

For detailed market insights: https://www.fortunebusinessinsights.com/industry-reports/neurovascular-devices-interventional-neurology-market-101684

Market Drivers and Restraints

The increasing prevalence of neurovascular disorders is a major factor driving market growth. Stroke, cerebral aneurysms, and other cerebrovascular conditions are becoming increasingly common, particularly among older individuals. According to the World Health Organization (WHO), approximately one in four individuals is expected to experience a stroke during their lifetime.

Additionally, rising awareness regarding early diagnosis, favorable reimbursement policies, and government initiatives promoting stroke management are encouraging patients to seek timely treatment.

Technological advancements are another important growth driver. Manufacturers are investing in innovative embolization coils, aspiration catheters, stent retrievers, and revascularization devices to improve treatment efficiency and patient outcomes.

However, delayed diagnosis, limited access to specialized healthcare facilities, high treatment costs, and shortages of trained neurointerventional specialists may restrict market expansion, particularly in developing economies.

Regional Insights

North America: North America dominated the global market with a 43.60% share in 2025, generating USD 1.78 billion in revenue. The regional market is projected to reach USD 1.96 billion in 2026. Strong healthcare infrastructure, favorable reimbursement policies, higher diagnosis rates, and the presence of leading medical device manufacturers support regional dominance. The U.S. market is projected to reach USD 1.88 billion in 2026.

Europe: Europe accounted for 26.00% of the global market in 2025, generating USD 1.06 billion. The market is expected to reach USD 1.16 billion in 2026. Increasing product approvals, growing awareness of neurological conditions, and expanding access to advanced interventional procedures are supporting regional growth.

Asia Pacific: Asia Pacific generated USD 0.96 billion in 2025, representing 23.60% of the global market. The market is projected to reach USD 1.05 billion in 2026. Improving healthcare infrastructure, rising awareness, and increasing investments by international manufacturers are driving adoption across China, India, and Japan.

Latin America: The market generated USD 0.17 billion in 2025, accounting for 4.30% of global revenue. Growing awareness, improving healthcare facilities, and the introduction of advanced neurovascular devices are supporting regional development.

Middle East & Africa: The region accounted for 2.50% of the global market in 2025, reaching USD 0.10 billion. Investments in healthcare infrastructure and increasing access to specialized neurological treatments are expected to support future growth.

The neurovascular devices market is expected to benefit from increasing adoption of minimally invasive procedures, mechanical thrombectomy, and advanced embolization technologies. Growing clinical research, product innovation, and strategic collaborations among medical device manufacturers are likely to accelerate the commercialization of next-generation devices.

Furthermore, expanding stroke treatment infrastructure in emerging economies and increasing investments in specialized neurointerventional centers will create additional growth opportunities.

Competitive Landscape

Leading companies are focusing on product innovation, clinical research, regulatory approvals, and strategic partnerships to strengthen their market positions. Stryker, Medtronic, Penumbra, and MicroPort Scientific Corporation are emphasizing advanced neurovascular technologies to improve treatment outcomes and expand their global presence.

Key Industry Developments

  • January 2023: Penumbra, Inc. launched its FDA-approved Lightning Flash mechanical thrombectomy system.
  • November 2022: iVascular expanded its neurovascular product portfolio with several CE-marked devices, including microcatheters and thrombectomy products.
  • October 2022: Medtronic introduced its Neurovascular Co-Lab Platform to accelerate innovation in stroke care.
  • September 2022: Penumbra announced the launch of RED reperfusion catheters in Europe.
  • June 2022: MicroPort Scientific Corporation completed the first commercial implantation of its Numen Coil Embolization System in the U.S.